September 8, 2026
Photo provided by SightGlass Vision
SightGlass Vision’s DOT™ spectacle lenses for myopia control have won a Gold Stevie® Award for Technology Breakthrough of the Year. Presented in the Healthcare Technology category at the 2026 Stevie® Awards for Technology Excellence, the award recognizes DOT lenses’ novel contrast management approach to slowing myopia progression in children and is praised by judges as a “standout healthcare technology innovation.”
SightGlass Vision’s winning entry, “DOT Spectacle Lenses Offer a Groundbreaking New Approach to Protecting Children’s Eyesight,” highlighted the company’s landmark clinical research, rapid adoption of the lens and continued investment in educating eyecare professionals on the power of contrast management for myopia control. Among the achievements cited: new two-year data showing that DOT spectacle lenses saved more than 1.00D of myopia progression on average after two years in Chinese children aged 6 to 10.1*
“Myopia is one of the biggest public health issues facing children today, and it’s incredibly rewarding to see DOT lenses recognized for the impact they’re making,” said Andrew Sedgwick, CEO of SightGlass Vision. “This recognition belongs to the eyecare professionals and families who trust DOT lenses, and it reaffirms why this work is so crucial: we’re slowing myopia progression in children now, to protect their eye health today and for years to come.”
Health Technology Recognition
This award follows another recent honor: SightGlass Vision was named a finalist for Healthtech Company of the Year at the 2026 U.K. Business Tech Awards, which recognizes organizations driving meaningful innovation in health technology.
The Stevie® Awards for Technology Excellence celebrate the remarkable accomplishments of individuals, teams and organizations shaping the future of technology across all industry sectors. This year, more than 700 nominations from organizations in 37 countries and territories were submitted for consideration in a wide range of tech-related categories. SightGlass Vision’s Gold win places it alongside some of tech’s most recognizable names, including Apple, Microsoft and IBM, among this year’s honorees. The winners will be honored during a prestigious recognition dinner on October 28 in Paris, France.
For more information about the Stevie® Awards for Technology Excellence and to view the full list of winners, visit http://Tech.StevieAwards.com.
References
*Prescribed DOT lens wear time was 10 hours per day. LS mean progression difference of 1.01D between test and control groups.
DOT lenses are not available for sale in all countries, including in the U.S.
Diffusion Optics Technology and DOT are trademarks of SightGlass Vision, Inc.© 2026 SightGlass Vision, Inc. All Rights Reserved.
1 SGV data on file 2026. Control of myopia using contrast modulation spectacle lenses in a Chinese population (n = 172 (6-10 years: 117), 5 sites in China). Overall patient population aged 6–13 years. The clinical trial was designed to compare DOT lenses with conventional single vision lenses to evaluate their continued safety and efficacy in Chinese children.
Read the latest myopia news here
